The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Christopher Ross Redhead - goetzpartners securities Limited, Research Division - Analyst
: Yes, sorry, I got booted out of the call for a little while, so I hope I haven't -- ask something that's already been asked. Just in terms of this -- just kind
of interested, very interested in the combination therapies that you talked about. As I understand, the antibody you've done those studies in is
similar to the Lilly one, is that the case? It's a N3pE antibodies, is that right?
Question: Christopher Ross Redhead - goetzpartners securities Limited, Research Division - Analyst
: Right. Actually, so it's going to kind of getting at was -- you've got this very interesting data with Lecanemab which it's -- you're now looking at the
soluble -- do you have any sense of how much Lecanemab is taking out the N3pE. I don't know whether that -- if there's any data on that. because
it's kind of interesting that, that antibody works and actually the combination of your product would that maybe have an even broader effect given
that it's a different -- that the antibodies has a different target.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
SEPTEMBER 30, 2022 / 1:00PM, VVY.AS - Q2 2022 Vivoryon Therapeutics NV Earnings Call
I just sort of kind of thinking about the different combinations, all these different combinations that you can sit in the middle of this, essentially?
Question: Christopher Ross Redhead - goetzpartners securities Limited, Research Division - Analyst
: It's a confirmation. That's kind of what I was kind of thinking about was that actually the Canada is, by its nature, also kind of not specifically targeting,
but is taking out the N3pE in a much larger way than some of the other antibodies, right? Okay, that's so it's actually kind of confirmatory in that
sense that the N3pE really is the target -- or is -- has the potential that we all hope for?
Question: Christopher Ross Redhead - goetzpartners securities Limited, Research Division - Analyst
: The other sort of other quick question that I mean to ask sometimes when you're doing your drug is oral, did that help with process because
presumably you could -- the patients didn't have -- didn't have to go into a hospital presumably to get there necessarily to get their infusions and
things. Is that the case that you could more -- sorry.
Question: Christopher Ross Redhead - goetzpartners securities Limited, Research Division - Analyst
: Yes. So huge advantage, particularly in this patient population in an elderly patient population, which we know are, in any case, susceptible to
these kinds of infections and at any stage, you want to keep them out of the hospital, right?
|
